The market knows what fair value is. No doubt they were involved...

The market knows what fair value is. No doubt they were involved in the raising, and desperately want to dump their shares. Nice try.

The truth is that PI-88 has now been confirmed as a much more narrowly focussed drug, and failed to meet any endpoints in a cancer trial of the most closely-related tissue type. The impact on potential revenue is devastating, and there is no way of sugar-coating it. PI-88 was priced as a drug for multiple conditions, and now it's been demonstrated as merely a specialty drug, with a small target market.

Good luck partnering a drug without broad efficacy. It just doesn't happen.

All hope now rests with their next-generation compound. Price target $1.50.